Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists

OBJECTIVE: Acute myeloid leukemia (AML) is primarily a disease of older adults. These patients may not be candidates for intensive treatment, and there has been an ongoing need for treatment options for this group. We review the use of glasdegib, a hedgehog-pathway inhibitor available for use in com...

Descripción completa

Detalles Bibliográficos
Autores principales: Relias, Valerie, McBride, Ali, Newman, Matthew J, Paul, Shilpa, Saneeymehri, Seyyedeh, Stanislaus, Genique, Tobin, Jennifer, Hoang, Caroline J, Ryan, Joanne C, Galinsky, Ilene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008421/
https://www.ncbi.nlm.nih.gov/pubmed/33215562
http://dx.doi.org/10.1177/1078155220973737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008421/
https://www.ncbi.nlm.nih.gov/pubmed/33215562
http://dx.doi.org/10.1177/1078155220973737

Ejemplares similares